Construction of a prospective cohort for endometriosis and development of a multimodal data-driven artificial intelligence model for early diagnosis

注册号:

Registration number:

ChiCTR2600126725 

最近更新日期:

Date of Last Refreshed on:

2026-06-15 10:15:50 

注册时间:

Date of Registration:

2026-06-15 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

子宫内膜异位症前瞻性队列建设与多模态数据驱动的早期诊断人工智能模型开发

Public title:

Construction of a prospective cohort for endometriosis and development of a multimodal data-driven artificial intelligence model for early diagnosis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

子宫内膜异位症前瞻性队列建设与多模态数据驱动的早期诊断人工智能模型开发

Scientific title:

Construction of a prospective cohort for endometriosis and development of a multimodal data-driven artificial intelligence model for early diagnosis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

杨莹莹 

研究负责人:

王薇 

Applicant:

Yingying Yang 

Study leader:

Wei Wang 

申请注册联系人电话:

Applicant telephone:

+86 13916504688

研究负责人电话:

Study leader's telephone:

+86 20 83062650

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yingyingyang@tongji.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

gyfyywangwei@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国上海市浦东新区高科西路2699号

研究负责人通讯地址:

中国上海市浦东新区高科西路2699号

Applicant address:

No. 2699, Gaoke West Road, Pudong New Area, Shanghai, China

Study leader's address:

No. 2699, Gaoke West Road, Pudong New Area, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海市第一妇婴保健院

Applicant's institution:

Shanghai First Maternity and Infant Health Care Hospital

研究负责人所在单位:

上海市第一妇婴保健院

Affiliation of the Leader:

Shanghai First Maternity and Infant Health Care Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2026)伦审第(093)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海市第一妇婴保健院医学伦理委员会

Name of the ethic committee:

Ethics Committee, Shanghai First Maternity and Infant Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2026-03-23 00:00:00

伦理委员会联系人:

李春林

Contact Name of the ethic committee:

Li Chunlin

伦理委员会联系地址:

中国上海市浦东新区高科西路2699号

Contact Address of the ethic committee:

No. 2699, Gaoke West Road, Pudong New Area, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 20261211

伦理委员会联系人邮箱:

Contact email of the ethic committee:

clli18@fudan.edu.cn

研究实施负责(组长)单位:

上海市第一妇婴保健院

Primary sponsor:

Shanghai First Maternity and Infant Health Care Hospital

研究实施负责(组长)单位地址:

中国上海市浦东新区高科西路2699号

Primary sponsor's address:

No. 2699, Gaoke West Road, Pudong New Area, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市第一妇婴保健院

具体地址:

中国上海市浦东新区高科西路2699号

Institution
hospital:

Shanghai First Maternity and Infant Health Care Hospital

Address:

No. 2699, Gaoke West Road, Pudong New Area, Shanghai, China

经费或物资来源:

自筹

Source(s) of funding:

Self-funding

Target disease:

Dysmenorrhea, pelvic pain, endometriosis

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

1) 建立前瞻性子宫内膜异位症高危队列,识别内异症发生的关键风险因素,为早期干预提供靶点。 2) 前瞻性采集系列外周血生物样本,探索可用于早期预测和诊断的潜在生物标志物 3) 整合临床疼痛特征、心理评估数据与分子标志物等多模态信息,应用人工智能算法开发辅助早期诊断和风险分层的预测工具。 4) 在真实世界环境中评估现有治疗策略的有效性和对疾病进程的影响,为临床决策提供证据。  

Objectives of Study:

1) Establish a prospective high-risk cohort for endometriosis to identify the key risk factors for the occurrence of endometriosis and provide targets for early intervention. 2) Collect a series of peripheral blood biological samples prospectively to explore potential biomarkers that can be used for early prediction and diagnosis. 3) Integrate multimodal information such as clinical pain characteristics, psychological assessment data, and molecular markers, and apply artificial intelligence algorithms to develop predictive tools for early diagnosis and risk stratification. 4) Evaluate the effectiveness and impact on the disease process of existing treatment strategies in real-world settings to provide evidence for clinical decision-making.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.女性;
2.年龄14-30岁;
3.未孕未育;
4.无流产史;
5.存在周期性或非周期性痛经或慢性盆腔痛;
6.自愿签署知情同意书(未成年人需监护人签字);

Inclusion criteria

1. Female; 2. Age 14-30 years old; 3. Unmarried and childless; 4. No history of miscarriage; 5. Present with periodic or non-periodic dysmenorrhea or chronic pelvic pain; 6. Voluntarily sign the informed consent form (for minors, the signature of the guardian is required);

排除标准:

1.无月经初潮;
2.近6个月内妊娠史;
3.合并急性炎症、严重脏器衰竭、血液病、自身免疫病、传染病、恶性肿瘤等;

Exclusion criteria:

1.Absence of menarche (first menstrual period);
2.Pregnancy history within the past 6 months;
3.Companied by acute inflammation, severe organ failure, blood diseases, autoimmune diseases, infectious diseases, and malignant tumors, etc.

研究实施时间:

Study execute time:

From 2026-01-01 00:00:00 To 2028-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-15 00:00:00 To 2028-12-31 00:00:00  

干预措施:

Interventions:

组别:

观察组

样本量:

0

Group:

Observation group

Sample size:

干预措施:

干预措施代码:

Intervention:

N/A

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

上海市第一妇婴保健院 

单位级别:

三级甲等 

Institution
hospital:

Shanghai First Maternity and Infant Health Care Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖北 

市(区县):

 

Country:

China 

Province:

Hubei 

City:

 

单位(医院):

华中科技大学同济医学院附属同济医院 

单位级别:

三级甲等 

Institution
hospital:

Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

子宫内膜异位症确诊

指标类型:

主要指标

Outcome:

Diagnosis of endometriosis

Type:

Primary indicator

测量时间点:

入组后3年

测量方法:

内异症确诊(手术病理/影像学诊断)

Measure time point of outcome:

After being included in the group, for a period of 3 years

Measure method:

Diagnosis of endometriosis (surgical pathology/imaging diagnosis)

指标中文名:

整合多模态数据的人工智能预测模型

指标类型:

次要指标

Outcome:

An artificial intelligence prediction model for integrating multimodal data

Type:

Secondary indicator

测量时间点:

入组后3年

测量方法:

AI机器算法构建预测模型

Measure time point of outcome:

After being included in the group, for a period of 3 years

Measure method:

Construction of prediction model

指标中文名:

基于影像学(超声/MRI)临床诊断的内异症

指标类型:

次要指标

Outcome:

Endometriosis diagnosed based on imaging (ultrasound/MRI) clinical examinatio

Type:

Secondary indicator

测量时间点:

每年

测量方法:

进行标准化盆腔超声复查

Measure time point of outcome:

Every year

Measure method:

standardized pelvic ultrasound re-examination

指标中文名:

肠道及阴道微生态组成的纵向动态变化及其与疾病发生的关联强度

指标类型:

次要指标

Outcome:

The longitudinal dynamic changes in the composition of intestinal and vaginal microecologies and their association strength with the occurrence of diseases

Type:

Secondary indicator

测量时间点:

每6个月

测量方法:

采集阴道拭子和肠道拭子

Measure time point of outcome:

Every six months

Measure method:

Collect vaginal swabs and intestinal swabs

指标中文名:

疼痛症状评分

指标类型:

次要指标

Outcome:

Pain symptom score

Type:

Secondary indicator

测量时间点:

每6个月

测量方法:

完成相关量表:疼痛(VAS评分)、焦虑量表(SAS)、抑郁量表(SDS)、生活质量量表(SF-12)、简版麦吉尔疼痛量表(SF-MPQ)等

Measure time point of outcome:

Every six months

Measure method:

Complete the relevant scales: pain (VAS score), anxiety scale (SAS), depression scale (SDS), quality of life scale (SF-12), simplified McGill pain scale (SF-MPQ), etc.

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

阴道拭子

组织:

Sample Name:

Vaginal swab

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

肠道拭子

组织:

Sample Name:

Intestinal swab

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

外周血

组织:

Sample Name:

Blood sample

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 14 years
最大 Max age 30 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

N/A

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic data capture, EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-06-15 10:15:37